Lyphe Dispensary has expanded its Noidecs V collection, a patient-focused, cost-effective medical cannabis range developed based on user feedback.
Following the success of Noidecs Vital Platinum OG, launched in June 2024, the extended line includes four new products: VOne, VTwo, VThree, and VFour. These full-flower cannabis options, previously known under the “Vital” label, simplify the selection process for patients.
VOne is perfect for beginners or those needing mild relief, while VFour, with the highest THC level, caters to experienced users. The tiered design allows patients to select the most suitable product for their therapeutic needs, all at an affordable price.
“Patients are advocating for lower cost, yet sustainable options, and we want them to know that Lyphe is not only listening but taking action,” said Hayley Thompson, Managing Director at Lyphe Clinic. “The Noidecs VOne-VFour line aims to bridge the gap between quality and cost, offering patients a reliable and accessible option for managing their health conditions.”
Lyphe ensures affordability without compromising quality or freshness, leveraging scaling efficiencies and a streamlined supply chain to keep prices stable while maintaining consistent THC levels.
Regulatory updates from the MHRA mean “Vital” branding will evolve, though the core principles behind the range remain unchanged.
Noidecs VThree launches in Winter 2024, with the full collection available to patients by early 2025. Additional details will follow shortly.
